Alport's syndrome, Goodpasture's syndrome, and type IV collagen

New England Journal of Medicine

Volumn 348, Issue 25, 2003, Pages 2543-2556

  Hudson, Billy G ^a   Tryggvason, Karl ^b   Sundaramoorthy, Munirathinam ^a   Neilson, Eric G ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; GOODPASTURE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ALPORT SYNDROME; BASEMENT MEMBRANE; BIOCHEMISTRY; COLLAGEN DISEASE; COLLAGEN METABOLISM; CYTOKINE PRODUCTION; DISEASE MODEL; EPITHELIUM; GENE THERAPY; GLOMERULUS BASEMENT MEMBRANE; GOODPASTURE SYNDROME; HUMAN; IMMUNOMODULATION; MACROPHAGE MIGRATION INHIBITION; MOLECULAR DYNAMICS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; PROTOMER; REVIEW; SYNDROME DELINEATION; T LYMPHOCYTE ACTIVATION;

ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; AUTOANTIBODIES; BASEMENT MEMBRANE; BIOPSY; COLLAGEN TYPE IV; HUMANS; KIDNEY; KIDNEY GLOMERULUS; MOLECULAR STRUCTURE; NEPHRITIS, HEREDITARY;

EID: 0038469583     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra022296     Document Type: Review

References (140)

1. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
2. Davies JA, Garrod DR. Molecular aspects of the epithelial phenotype. Bioessays 1997;19:699-704.
3. Schock F, Perrimon N. Molecular mechanisms of epithelial morphogenesis. Annu Rev Cell Dev Biol 2002;18:463-93.
4. Yurchenco PD, Smirnov S, Mathus T. Analysis of basement membrane self-assembly and cellular interactions with native and recombinant glycoproteins. Methods Cell Biol 2002;69:111-44.
5. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med 1998;76:253-65.
6. Soininen K, Haka-Risku T, Prockop DJ, Tryggvason K. Complete primary structure of the alpha 1-chain of human basement membrane (type IV) collagen. FEBS Lett 1987;225:188-94.
7. Hostikka SL, Tryggvason K. The complete primary structure of the alpha 2 chain of human type 1V collagen and comparison with the alpha 1(IV) chain. J Biol Chem 1988;263:19488-93.
8. Mariyama M, Leinonen A, Mochizuki T, Tryggvason K, Reeders ST. Complete primary structure of the human alpha 3(IV) collagen chain: coexpression of the alpha 3(IV) and alpha 4(IV) collagen chains in human tissues. J Biol Chem 1994;269:23013-7.
9. Leinonen A, Mariyama M, Mochizuki T, Tryggvason K, Reeders ST. Complete primary structure of the human type IV collagen alpha 4(IV) chain: comparison with structure and expression of the other alpha (IV) chains. J Biol Chem 1994;269:26172-7.
10. Hostikka, SL, Eddy RL, Byers MG, Hoyhtya M, Shows TB, Tryggvason K. Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome. Proc Natl Acad Sci U S A 1990;87:1606-10.
11. Myers JC, Jones TA, Pohjolainen ER, et al. Molecular cloning of alpha 5(IV) collagen and assignment of the gene to the region of the X chromosome containing the Alport syndrome locus. Am J Hum Genet 1990;46:1024-33.
12. Zhou J, Ding M, Zhao Z, Reeders ST. Complete primary structure of the sixth chain of human basement membrane collagen, alpha 6(IV): isolation of the cDNAs for alpha 6(IV) and comparison with five other type IV collagen chains. J Biol Chem 1994;269:13193-9.
13. Oohashi T, Sugimoto M, Mattei MG, Ninomiya Y. Identification of a new collagen IV chain, alpha 6(IV), by cDNA isolation and assignment of the gene to chromosome Xq22, which is the same locus for COL4A5. J Biol Chem 1994;269:7520-6.
14. Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases: molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993;268:26033-6.
15. Alport AC. Hereditary familial congenital haemorrhagic nephritis. BMJ 1927;1:504-6.
16. Spear GS. Pathology of the kidney in Alport's syndrome. Pathol Annu 1974;9:93138.
17. Idem. Alport's syndrome: a consideration of pathogenesis. Clin Nephrol 1973;1:336-7.
18. Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 2002;61:1947-56.
19. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000;11:649-57.
20. Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990;248:1224-7.
21. Lemmink HH, Nillesen WN, Mochizuki T, et al. Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest 1996;98:1114-8.
22. Buzza M, Wilson D, Savige J. Segregation of hematuria in thin basement membrane disease with haplotypes at the loci for Alport syndrome. Kidney Int 2001;59:1670-6.
23. Badenas C, Praga M, Tazon B, et al. Mutations in the COL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 2002;13:1248-54.
24. Dagher H, Buzza M, Colville D, et al. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 2001;38:1217-28.
25. Stanton MC, Tange JD. Goodpasture's syndrome: pulmonary hemorrhage associated with glomerulonephritis. Austr Ann Med 1958;7:132-44.
26. Goodpasture EW. The pathology of pneumonia accompanying influenza. U S Naval Med Bull 1919;13:177-97.
27. Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol 1999;10:2446-53.
28. Savage CO, Pusey CD, Bowman C, Rees AJ, Lockwood CM. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986;292:301-4.
29. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1988;263:13374-80.
30. Kalluri R, Wilson CB, Weber M, et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 1995;6:1178-85.
31. Gunwar S, Bejarano PA, Kalluri R, et al. Alveolar basement membrane: molecular properties of the noncollagenous domain (hexamer) of collagen IV and its reactivity with Goodpasture autoantibodies. Am J Respir Cell Mol Biol 1991;5:107-12.
32. Butkowski RJ, Wieslander J, Kleppel M, Michael AF, Fish AJ. Basement membrane collagen in the kidney: regional localization of novel chains related to collagen IV. Kidney Int 1989;35:1195-202.
33. Kalluri R, Melendez E, Rumpf KW, et al. Specificity of circulating and tissue-bound autoantibodies in Goodpasture syndrome. Proc Assoc Am Physicians 1996;108:134-9.
34. McCoy PC, Johnson HK, Stone WJ, Wilson CB. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 1982;21:642-52.
35. Boutaud A, Borza DB, Bondar O, et al. Type IV collagen of the glomerular basement membrane: evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 2000;275:30716-24.
36. Borza DB, Bondar O, Todd P, et al. Quaternary organization of the Goodpasture autoantigen, the α3(IV) collagen chain: sequestration of two cryptic autoepitopes by intraprotomer interactions with the α4 and α5 NC1 domains. J Biol Chem 2002;277:40075-83.
37. Borza DB, Bondar O, Ninomiya Y, et al. The NC1 domain of collagen IV encodes a novel network composed of the alpha 1, alpha 2, alpha 5, and alpha 6 chains in smooth muscle basement membranes. J Biol Chem 2001;276:28532-40.
38. Kefalides NA. A collagen of unusual composition and a glycoprotein isolated from canine glomerular basement membrane. Biochem Biophys Res Commun 1966;22:26-32.
39. Timpl R, Wiedemann H, van Delden V, Furthmayr H, Kuhn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur J Biochem 1981;120:203-11.
40. Yurchenco PD, Furthmayr H. Self-assembly of basement membrane collagen. Biochemistry 1984;23:1839-50.
41. Tryggvason K, Robey PG, Martin GR. Biosynthesis of type IV procollagens. Biochemistry 1980;19:1284-9.
42. Butkowski RJ, Langeveld JP, Wieslander J, Hamilton J, Hudson BG. Localization of the Goodpasture epitope to a novel chain of basement membrane collagen. J Biol Chem 1987;262:7874-7.
43. Gunwar S, Saus J, Noelken ME, Hudson BG. Glomerular basement membrane: identification of a fourth chain, alpha 4, of type IV collagen. J Biol Chem 1990;265:5466-9.
44. Peissel B, Geng L, Kalluri R, et al. Comparative distribution of the alpha 1(IV), alpha 5(IV), and alpha 6(IV) collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. J Clin Invest 1995;96:1948-57.
45. Langeveld JP, Noelken ME, Hard K, et al. Bovine glomerular basement membrane: location and structure of the asparaginelinked oligosaccharide units and their potential role in the assembly of 7 S collagen IV tetramer. J Biol Chem 1991;266:2622-31.
46. Nayak BR, Spiro RG. Localization and structure of the asparagine-linked oligosaccharides of type IV collagen from glomerular basement membrane and lens capsule. J Biol Chem 1991;266:13978-87.
47. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997;99:2470-8.
48. Sundaramoorthy M, Meiyappan M, Todd P, Hudson BG. Crystal structure of NC1 domains: structural basis for type IV collagen assembly in basement membranes. J Biol Chem 2002;277:31142-53.
49. Than ME, Henrich S, Huber R, et al. The 1.9-A crystal structure of the noncollagenous (NC1) domain of human placenta collagen IV shows stabilization via a novel type of covalent Met-Lys cross-link. Proc Natl Acad Sci U S A 2002;99:6607-12.
50. Guo XD, Johnson B, Kramer JM. Embryonic lethality caused by mutations in basement membrane collagen of C. elegans. Nature 1991;349:707-9.
51. Zhang X, Hudson BG, Sarras MP Jr. Hydra cell aggregate development is blocked by selective fragments of fibronectin and type IV collagen. Dev Biol 1994;164:10-23.
52. Netzer KO, Suzuki K, Itoh Y, Hudson BG, Khalifah RG. Comparative analysis of the noncollagenous NC1 domain of type IV collagen: identification of structural features important for assembly, function, and pathogenesis. Protein Sci 1998;7:1340-51.
53. Fowler SJ, Jose S, Zhang X, Deutzmann R, Sarras MP Jr, Boot-Handford RP. Characterization of hydra type IV collagen: type IV collagen is essential for head regeneration and its expression is up-regulated upon exposure to glucose. J Biol Chem 2000;275:39589-99.
54. Kalluri R, Gattone VH II, Hudson BG. Identification and localization of type IV collagen chains in the inner ear cochlea. Connect Tissue Res 1998;37:143-50.
55. Cosgrove D, Samuelson G, Meehan DT, et al. Ultrastructural, physiological, and molecular defects in the inner ear of a geneknockout mouse model for autosomal Alport syndrome. Hear Res 1998;121:84-98.
56. Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain: normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994;144:986-96.
57. Ninomiya Y, Kagawa M, Iyama K, et al. Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. J Cell Biol 1995;130:121929.
58. Miner JH, Sanes JR. Collagen IV alpha 3, alpha 4, and alpha 5 chains in rodent basal laminae: sequence, distribution, association with laminins, and developmental switches. J Cell Biol 1994;127:879-91.
59. Harvey SJ, Zheng K, Sado Y, et al. Role of distinct type IV collagen networks in glomerular development and function. Kidney Int 1998;54:1857-66.
60. Williamson DAJ. Alport's syndrome of hereditary nephritis with deafness. Lancet 1961;2:1321-3.
61. Grunfeld JP. Contemporary diagnostic approach in Alport's syndrome. Ren Fail 2000;22:759-63.
62. Kashtan CE. Familial hematuric syndromes - Alport syndrome, thin glomerular basement membrane disease and Fechtner/Epstein syndromes. Contrib Nephrol 2001;136:79-99.
63. Martin P, Heiskari N, Zhou J, et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 1998;9:2291-301.
64. Lemmink HH, Mochizuki T, van den Heuvel LP, et al. Mutations in the type IV collagen alpha 3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet 1994;3:1269-73.
65. Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994;8:77-81.
66. Antignac C, Zhou J, Sanak M, et al. Alport syndrome and diffuse leiomyomatosis: deletions in the 5′ end of the COL4A5 collagen gene. Kidney Int 1992;42:1178-83.
67. Zhou J, Mochizuki T, Smeets H, et al. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science 1993;261:1167-9.
68. Zhang X, Zhou J, Reeders ST, Tryggvason K. Structure of the human type IV collagen COL4A6 gene, which is mutated in Alport syndrome-associated leiomyomatosis. Genomics 1996;33:473-9.
69. McIntosh I, Dreyer SD, Clough MV, et al. Mutation analysis of LMX1B gene in nailpatella syndrome patients. Am J Hum Genet 1998;63:1651-8.
70. Hamano, Y, Grunkemeyer JA, Sudhakar A, et al. Determinants of vascular permeability in the kidney glomerulus. J Biol Chem 2002;277:31154-62.
71. Miner JH, Morello R, Andrews KL, et al. Transcriptional induction of slit diaphragm genes by LMX1B is required in podocyte differentiation. J Clin Invest 2002;109:106572.
72. Morello R, Zhou G, Dreyer SD, et al. Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome. Nat Genet 2001;27:205-8.
73. Kashtan CE, Kleppel MM, Gubler MC. Immunohistologic findings in Alport syndrome. Contrib Nephrol 1996;117:142-53.
74. Kalluri R, Cantley LG, Kerjaschki D, Neilson EG. Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome. J Biol Chem 2000;275:20027-32.
75. Huang T, Cheng AG, Stupak H, et al. Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int J Dev Neurosci 2000;18:259-70.
76. Reddan JR, Steiger CA, Dziedzic DC, Gordon SR. Regional differences in the distribution of catalase in the epithelium of the ocular lens. Cell Mol Biol (Noisy-le-grand) 1996;42:209-19.
77. Gunwar S, Ballester F, Noelken ME, Sado Y, Ninomiya Y, Hudson BG. Glomerular basement membrane: identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J Biol Chem 1998;273:8767-75.
78. Kim KH, Kim Y, Gubler MC, et al. Structural-functional relationships in Alport syndrome. J Am Soc Nephrol 1995;5:1659-68.
79. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.
80. Zeisberg M, Bonner G, Maeshima Y, et al. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001;159:1313-21.
81. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Renal fibrosis: extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 2002;160:2001-8.
82. Strutz, F, Okada H, Lo CW, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995;130:393-405.
83. Iwano, M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-50.
84. Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotypephenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002;17:1218-27.
85. Hasstedt SJ, Atkin CL, San Juan AC Jr. Genetic heterogeneity among kindreds with Alport syndrome. Am J Hum Genet 1986;38:940-53.
86. Colville DJ, Savige J. Alport syndrome: a review of the ocular manifestations. Ophthalmic Genet 1997;18:161-73.
87. Rumpelt HJ. Alport's syndrome: specificity and pathogenesis of glomerular basement membrane alterations. Pediatr Nephrol 1987;1:422-7.
88. Dische FE, Anderson VE, Keane SJ, Taube D, Bewick M, Parsons V. Incidence of thin membrane nephropathy: morphometric investigation of a population sample. J Clin Pathol 1990;43:457-60.
89. Adler L, Mathew R, Futterweit S, et al. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion. BMC Nephrol 2002;3:2.
90. Byrne MC, Budisavljevic MN, Fan Z, Self SE, Ploth DW. Renal transplant in patients with Alport's syndrome. Am J Kidney Dis 2002;39:769-75.
91. Kalluri R, Torre A, Shield CF III, et al. Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies. Transplantation 2000;69:679-83.
92. Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992;42:179-87.
93. Kashtan CE, McEnery PT, Tejani A, Stablein DM. Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1995;9:679-84.
94. van Setten G. Anterior lenticonus: histological evaluation and approach for cataract surgery. J Cataract Refract Surg 2001;27:1071-5.
95. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973;3:74-89.
96. Wieslander J, Barr JF, Butkowski RJ, et al. Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen. Proc Natl Acad Sci U S A 1984;81:3838-42.
97. Kalluri P, Danoff TM, Okada H, Neilson EG. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 1997;100:2263-75.
98. Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999;56:1638-53.
99. Wong D, Phelps RG, Turner AN. The Goodpasture antigen is expressed in the human thymus. Kidney Int 2001;60:1777-83.
100. Salama AD, Chaudhry AN, Ryan JJ, et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol 2001;12:1908-15.
101. Bolton WK, Luo AM, Fox PL, May WJ, Sturgill BC. Study of EHS type IV collagen lacking Goodpasture's epitope in glomerulonephritis in rats. Kidney Int 1995;47:40410.
102. Kalluri R, Petrides S, Wilson CB, et al. Anti-alpha 1 (IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med 1996;124:651-3.
103. Sado Y, Boutaud A, Kagawa M, Naito I, Ninomiya Y, Hudson BG. Induction of antiGBM nephritis in rats by recombinant alpha 3(IV)NC1 and alpha 4(IV)NC1 of type IV collagen. Kidney Int 1998;53:664-71. [Erratum, Kidney Int 1998;54:311.]
104. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 1967;126:9891004.
105. Almkuist RD, Buckalew VM Jr, Hirszel P, Maher JF, James PM, Wilson CB. Recurrence of anti-glomerular basement membrane antibody mediated glomerulonephritis in an isograft. Clin Immunol Immunopathol 1981;18:54-60.
106. Meyers KE, Allen J, Gehret J, et al. Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney Int 2002;61:1666-73.
107. Rutgers A, Meyers KE, Canziani G, Kalluri R, Lin J, Madaio MP. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV) NC1 collagen. Kidney Int 2000;58:115-22.
108. Netzer KO, Leinonen A, Boutaud A, et al. The Goodpasture autoantigen: mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem 1999;274:11267-74.
109. Hellmark T, Burkhardt H, Wieslander J. Goodpasture disease: characterization of a single conformational epitope as the target of pathogenic autoantibodies. J Biol Chem 1999;274:25862-8.
110. Borza DB, Netzer KO, Leinonen A, et al. The Goodpasture autoantigen: identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. J Biol Chem 2000;275:6030-7.
111. David M, Borza DB, Leinonen A, Belmont JM, Hudson BG. Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen: a molecular basis for the cryptic nature of the epitope. J Biol Chem 2001;276:6370-7.
112. Gunnarsson A, Hellmark T, Wieslander J. Molecular properties of the Goodpasture epitope. J Biol Chem 2000;275:30844-8.
113. Neilson EG, Kalluri R, Sun MJ, et al. Specificity of Goodpasture autoantibodies for the recombinant noncollagenous domains of human type IV collagen. J Biol Chem 1993;268:8402-5.
114. Kalluri R, Sun MJ, Hudson BG, Neilson EG. The Goodpasture autoantigen: structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen. J Biol Chem 1996;271:9062-8.
115. Wieslander J, Langeveld J, Butkowski R, Jodlowski M, Noelken M, Hudson BG. Physical and immunochemical studies of the globular domain of type IV collagen: cryptic properties of the Goodpasture antigen. J Biol Chem 1985;260:8564-70.
116. Stevenson A, Yaqoob M, Mason H, Pai P, Bell GM. Biochemical markers of basement membrane disturbances and occupational exposure to hydrocarbons and mixed solvents. QJM 1995;88:23-8.
117. Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983;2:1390-3.
118. Meyers KE, Kinniry PA, Kalluri P, Neilson EG, Madaio MP. Human Goodpasture anti-alpha3(IV)NC1 autoantibodies share structural determinants. Kidney Int 1998;53:402-7.
119. Derry CJ, Ross CN, Lombardi G, et al. Analysis of T cell responses to the autoantigen in Goodpasture's disease. Clin Exp Immunol 1995;100:262-8.
120. Remuzzi G, Zoja C, Bertani T. Glomerulonephritis. Curr Opin Nephrol Hypertens 1993;2:465-74.
121. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 1997;27:530-7.
122. Wu J, Hicks J, Ou C, Singleton D, Borillo I, Lou YH. Glomerulonephritis induced by recombinant collagen IV alpha 3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: a potential T cell-mediated mechanism. J Immunol 2001;167:2388-95.
123. Wu J, Hicks J, Borillo J, Glass WF II, Lou YH. CD4(+) T cells specific to a glomer ular basement membrane antigen mediate glomerulonephritis. J Clin Invest 2002;109:517-24.
124. Netzer KO, Merkel F, Weber M. Goodpasture syndrome and end-stage renal failure - to transplant or not to transplant? Nephrol Dial Transplant 1998;13:1346-8.
125. Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH. Protection against antiglomerular basement membrane (GBM)mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997;110:403-9.
126. Baricos WH, Cortez SL, Le QC, et al. Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. Arch Biochem Biophys 1991;288:468-72.
127. Timoshanko JR, Kitching AR, Holdsworth SR, Tipping PG. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J Am Soc Nephrol 2001;12:464-71.
128. Kitching AR, Ru Huang X, Turner AL, Tipping PG, Dunn AR, Holdsworth SR. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol 2002;13:350-8.
129. Holdsworth SR, Kitching AR, Tipping PG. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int 1999;55:1198-216.
130. Kitching AR, Tipping PG, Holdsworth SR. IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. Eur J Immunol 1999;29:1-10.
131. Timoshanko JR, Holdsworth SR, Kitching AR, Tipping PG. IFN-gamma production by intrinsic renal cells and bone marrowderived cells is required for full expression of crescentic glomerulonephritis in mice. J Immunol 2002;168:4135-41.
132. Isbel NM, Hill PA, Foti R, et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001;60:614-25.
133. Lockwood CM, Peters DK. Plasma exchange in glomerulonephritis and related vasculitides. Annu Rev Med 1980;31:167-79.
134. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134:1033-42.
135. Salama AD, Dougan T, Levy JB, et al. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 2002;39:1162-7.
136. Kalluri R, Meyers K, Mogyorosi A, Madaio MP, Neilson EG. Goodpasture syndrome involving overlap with Wegener's granulomatosis and anti-glomerular basement membrane disease. J Am Soc Nephrol 1997;8:1795-800.
137. Bosch X, Mirapeix E, Font J, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 1991;36:107-13.
138. Heikkila P, Tibell A, Morita T, et al. Adenovirus-mediated transfer of type IV collagen alpha5 chain cDNA into swine kidney in vivo: deposition of the protein into the glomerular basement membrane. Gene Ther 2001;8:882-90.
139. Reynolds J, Tam FW, Chandraker A, et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 2000;105:643-51.
140. Lan HY, Bacher M, Yang N, et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997;185:1455-65.